Compare IDEXX Laboratories, Inc. (IDXX) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Remitly Global Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while Remitly Global Inc trades at $24.27 (market cap $4.97B). The key difference: IDEXX Laboratories, Inc. is far larger — about 9.3× Remitly Global Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | RELY | |
|---|---|---|
Market Cap | $46.22B | $4.97B |
Sector | Health | Technology |
52-Week High | $766.68 | $25.93 |
52-Week Low | $526.44 | $12.20 |
Enterprise Value | $47.12B | $4.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
RELY trades at $24.25, up 4.8% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 results, with revenue of $495 million and adjusted EBITDA of $114.7 million, beating estimates. Revenue growth accelerated to 20% year-over-year, and net income turned positive in 2025, reaching $67.93 million. Recent initiatives include the launch of the Global Card and expansion in the UAE market.
The outlook is positive, driven by market share gains, new product launches, and improving profitability. Risks include competitive pressures in remittances and execution of growth initiatives. Analyst consensus is strongly bullish with a $31.00 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
